Multicenter Interventional Lymphangioleiomyomatosis Early Disease Trial (MILED) - DCC
多中心介入性淋巴管平滑肌瘤病早期疾病试验 (MILED) - DCC
基本信息
- 批准号:10249943
- 负责人:
- 金额:$ 29.14万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-09-20 至 2024-06-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAdverse eventAromatase InhibitorsBenignBiological MarkersCellsCessation of lifeChargeChronicChronic Myeloid LeukemiaClinicClinicalCommunitiesCystDataData Coordinating CenterDepartment of DefenseDevelopmentDiffuseDiseaseDisease ProgressionDoseEligibility DeterminationEnrollmentFDA approvedFRAP1 geneFloridaFoundationsFrightGasesGenesGleevecGoalsGrowthGrowth FactorImpairmentInformation DisseminationInfrastructureInternationalInterventionInvestmentsJapanKnowledgeLeadLungLung diseasesLymphangiogenesisLymphangioleiomyomatosisMagnetic Resonance ImagingMeasuresMolecularMutationNeoplasm MetastasisNeoplasmsPathogenesisPathway interactionsPatient ParticipationPatientsPerformancePharmaceutical PreparationsPhasePlacebosPleural effusion disorderPneumothoraxPrognostic MarkerPulmonary Function Test/Forced Expiratory Volume 1Pulmonary function testsQuality of lifeRandomizedRecurrenceRespiratory FailureSafetySerumSeveritiesSignal TransductionSirolimusSiteSmooth MuscleSmooth Muscle MyocytesSourceTimeToxic effectTuberous SclerosisUniversitiesVascular Endothelial Growth Factor DVital capacityWomanadvanced diseaseairway obstructionbiomarker discoverydata managementdiagnostic biomarkerdisabilityimprovedlung injurylung preservationlung volumemTOR InhibitormTOR inhibitionmiddle agemortalityneoplasticplacebo grouppreventprimary endpointprogramspulmonary functionpulmonary function declinerandomized placebo controlled trialrate of changerecruitrespiratorysecondary endpointside effecttargeted treatment
项目摘要
Project summary/abstract
Lymphangioleiomyomatosis (LAM) is low-grade metastasizing neoplasm of women, driven by activating
mutations in the mTOR pathway that result in cystic destruction of the lung. The benign appearing, mutation
bearing smooth muscle-like LAM cells that infiltrate the lung arise from an unknown source and execute a
program of matrix remodeling that leads to cyst formation, recurrent pneumothorax, chylous pleural effusion
and progressive respiratory failure. There has been tremendous progress in LAM in the past decade, including
a rich molecular understanding of disease pathogenesis, development of a diagnostic and prognostic
biomarker, and the discovery of a treatment. The randomized controlled Rare Lung Disease Consortium
(RLDC) Multicenter International LAM Efficacy of Sirolimus (MILES) Trial (Sponsor-FXM, IND 71,340)
demonstrated that mTOR inhibition with sirolimus is an effective suppressive therapy for LAM, stabilizing lung
function, functional performance, and quality of life in women with abnormal lung function. Side effects due to
sirolimus were common in MILES, although SAEs were balanced in the sirolimus and placebo groups. The
beneficial effects of sirolimus waned when the drug was held in the second year of the trial. Although the
primary eligibility criterion was forced expiratory volume in 1 second (FEV1) ≤ 70%, enrolled MILES patients
had more advanced respiratory impairment, with about half of lung function remaining (on average), limiting the
generalizability of the findings to mild disease. Fear of toxicities and lifelong therapy lead most clinicians and
patients to wait until lung function becomes abnormal before initiating sirolimus therapy to stabilize the
damaged lung. This approach is suboptimal and inadequate. The Multicenter Interventional LAM Early Disease
Trial (MILED) is phase III, randomized, placebo-controlled trial to determine if early, long term (2 yr), low dose
(1 mg/day) sirolimus treatment of patients with well-preserved lung function will safely prevent disease
progression. Sixty patients with normal FEV1 (FEV1>70%) will be enrolled and randomized to 1 mg/day
sirolimus or placebo, and followed for 2 years with pulmonary function testing every 4 months. The primary
endpoint will be the between-group (placebo vs. sirolimus) difference in the rate of change in FEV1 (in liters).
Secondary endpoints will include between group differences in adverse events, forced vital capacity, lung
volumes, diffusing capacity, serum VEGF-D, and early airflow obstruction assessed using hyper-polarized gas
MRI. The study will be conducted using the infrastructure created for the RLDC, using the Rare Lung Disease
Clinic Network, which is currently following over 1300 U.S. LAM patients and conducting the TRAIL trial. The
LAM Foundation will be an integral partner and will assist with study recruitment and patient participation. Data
will be managed by the University of South Florida Data Management and Coordinating Center. Successful
completion of these aims will define the safety and efficacy of low dose sirolimus in patients with normal lung
function, and determine if sirolimus can be used to prevent disease progression to symptomatic stages.
项目摘要/摘要
淋巴管肌瘤病(LAM)是一种女性低度转移性肿瘤,由活化引起
导致肺囊性破坏的mTOR途径突变。良性的出现、突变
具有平滑肌样LAM细胞的浸润性肺组织来自未知来源,并执行
导致囊肿形成、复发性气胸、乳糜性胸腔积液的基质重塑方案
和进行性呼吸衰竭。在过去的十年中,LAM取得了巨大的进步,包括
丰富了对疾病发病机制的分子认识,制定了诊断和预后
生物标记物,以及治疗方法的发现。随机对照的罕见肺病联合体
(RLDC)西罗莫司(MILES)试验的多中心国际LAM疗效(赞助商-FXM,IND 71,340)
证明西罗莫司抑制mTOR是一种有效的稳肺LAM抑制疗法。
肺功能异常妇女的功能、功能表现和生活质量。因以下原因而产生的副作用
西罗莫司在里程中很常见,尽管西罗莫司组和安慰剂组的SAE是平衡的。这个
当西罗莫司在试验的第二年被搁置时,其益处减弱。尽管
主要资格标准是1秒用力呼气量(FEV1)≤70%,登记的英里数患者
有更严重的呼吸损伤,大约一半的肺功能剩余(平均),限制了
对轻度疾病研究结果的概括性。对毒性的恐惧和终身治疗使大多数临床医生和
患者等到肺功能异常后再开始西罗莫司治疗以稳定肺功能
肺部受损。这种方法是次优的,也是不充分的。多中心介入治疗LAM早期病
试验(MILD)是第三阶段,随机、安慰剂对照试验,以确定早期、长期(2年)、低剂量
(1毫克/天)西罗莫司治疗肺功能保存良好的患者可安全预防疾病
进步。60名FEV1正常的患者(FEV1和GT;70%)将被纳入并随机服用1毫克/天
西罗莫司或安慰剂,随访2年,每4个月检测一次肺功能。初级阶段
终点将是两组之间(安慰剂与西罗莫司)FEV1变化率(升)的差异。
次要终点将包括两组之间在不良事件、用力肺活量、肺
用超极化气体评估容量、弥散能力、血清血管内皮生长因子-D和早期气流阻塞
核磁共振检查。这项研究将使用为RLDC创建的基础设施,使用罕见的肺部疾病
目前正在跟踪1300多名美国LAM患者并进行试验试验。这个
LAM基金会将成为不可或缺的合作伙伴,并将在研究招募和患者参与方面提供帮助。数据
将由南佛罗里达大学数据管理和协调中心管理。成功
完成这些目标将确定小剂量西罗莫司在肺功能正常的患者中的安全性和有效性
功能,并确定西罗莫司是否可以用于防止疾病进展到有症状的阶段。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JEFFREY P KRISCHER其他文献
JEFFREY P KRISCHER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JEFFREY P KRISCHER', 18)}}的其他基金
Limited Competition: Continued Follow-up of Subjects and Initiation of a Second Case-control Cohort in The Environmental Determinants of Diabetes in The Young Study (TEDDY)
有限的竞争:在年轻研究中糖尿病的环境决定因素(TEDDY)中继续对受试者进行随访并启动第二个病例对照队列
- 批准号:
10398923 - 财政年份:2021
- 资助金额:
$ 29.14万 - 项目类别:
Human gene transfer & macrophage cell transplantation therapy of hereditary PAP (hPAP)
人类基因转移
- 批准号:
10403442 - 财政年份:2021
- 资助金额:
$ 29.14万 - 项目类别:
Human gene transfer & macrophage cell transplantation therapy of hereditary PAP (hPAP)
人类基因转移
- 批准号:
10179934 - 财政年份:2021
- 资助金额:
$ 29.14万 - 项目类别:
Limited Competition: Continued Follow-up of Subjects and Initiation of a Second Case-control Cohort in The Environmental Determinants of Diabetes in The Young Study (TEDDY)
有限的竞争:在年轻研究中糖尿病的环境决定因素(TEDDY)中继续对受试者进行随访并启动第二个病例对照队列
- 批准号:
10227415 - 财政年份:2021
- 资助金额:
$ 29.14万 - 项目类别:
Human gene transfer & macrophage cell transplantation therapy of hereditary PAP (hPAP)
人类基因转移
- 批准号:
10702185 - 财政年份:2021
- 资助金额:
$ 29.14万 - 项目类别:
Follow-up on Subjects, Integrative Data Analysis and Measurement of Viral Antibodies in The Environmental Determinants of Diabetes in The Young Study (TEDDY)
青年糖尿病环境决定因素研究(TEDDY)中的受试者跟踪、综合数据分析和病毒抗体测量
- 批准号:
10392400 - 财政年份:2020
- 资助金额:
$ 29.14万 - 项目类别:
Follow-up on Subjects, Integrative Data Analysis and Measurement of Viral Antibodies in The Environmental Determinants of Diabetes in The Young Study (TEDDY)
青年糖尿病环境决定因素研究(TEDDY)中的受试者跟踪、综合数据分析和病毒抗体测量
- 批准号:
10260891 - 财政年份:2020
- 资助金额:
$ 29.14万 - 项目类别:
NIDDK Follow-up on Subjects and Immunological Assessments in The Environmental Determinants of Diabetes In The Young Study (TEDDY) (UC4)
NIDDK 青年糖尿病环境决定因素研究 (TEDDY) (UC4) 中受试者和免疫学评估的后续行动
- 批准号:
10088137 - 财政年份:2017
- 资助金额:
$ 29.14万 - 项目类别:
Data Coordinating Center for Type 1 Diabetes TrialNet (UC4)USF: TrialNet UC4-3
1 型糖尿病数据协调中心 TrialNet (UC4)USF:TrialNet UC4-3
- 批准号:
9506924 - 财政年份:2017
- 资助金额:
$ 29.14万 - 项目类别:
Multicenter Interventional Lymphangioleiomyomatosis Early Disease Trial (MILED) - DCC
多中心介入性淋巴管平滑肌瘤病早期疾病试验 (MILED) - DCC
- 批准号:
9743827 - 财政年份:2016
- 资助金额:
$ 29.14万 - 项目类别:
相似海外基金
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10707830 - 财政年份:2023
- 资助金额:
$ 29.14万 - 项目类别:
Hospital characteristics and Adverse event Rate Measurements (HARM) Evaluated over 21 years.
医院特征和不良事件发生率测量 (HARM) 经过 21 年的评估。
- 批准号:
479728 - 财政年份:2023
- 资助金额:
$ 29.14万 - 项目类别:
Operating Grants
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
分析 ECOG-ACRIN 不良事件数据,以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略
- 批准号:
10884567 - 财政年份:2023
- 资助金额:
$ 29.14万 - 项目类别:
AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection
AE2Vec:用于自动不良事件检测的医学概念嵌入和时间序列分析
- 批准号:
10751964 - 财政年份:2023
- 资助金额:
$ 29.14万 - 项目类别:
Understanding the real-world adverse event risks of novel biosimilar drugs
了解新型生物仿制药的现实不良事件风险
- 批准号:
486321 - 财政年份:2022
- 资助金额:
$ 29.14万 - 项目类别:
Studentship Programs
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10676786 - 财政年份:2022
- 资助金额:
$ 29.14万 - 项目类别:
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10440970 - 财政年份:2022
- 资助金额:
$ 29.14万 - 项目类别:
Improving Adverse Event Reporting on Cooperative Oncology Group Trials
改进肿瘤学合作组试验的不良事件报告
- 批准号:
10642998 - 财政年份:2022
- 资助金额:
$ 29.14万 - 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10482465 - 财政年份:2022
- 资助金额:
$ 29.14万 - 项目类别:
Expanding and Scaling Two-way Texting to Reduce Unnecessary Follow-Up and Improve Adverse Event Identification Among Voluntary Medical Male Circumcision Clients in the Republic of South Africa
扩大和扩大双向短信,以减少南非共和国自愿医疗男性包皮环切术客户中不必要的后续行动并改善不良事件识别
- 批准号:
10191053 - 财政年份:2020
- 资助金额:
$ 29.14万 - 项目类别:














{{item.name}}会员




